RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways

BUFFALO GROVE, Ill., Jan. 23, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) at the Keystone Symposia Series on PI 3-Kinase (PI3K) Signaling Pathways. The presentation titled “Validation of RES- 529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme” was presented on January 16, 2015. RES-529 is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that is capable of dissociating both TORC1 and TORC2. “The data presented help to understand the use of RES-529 and the validity of targeting the TORC1 and TORC2 protein complexes in a dissociative manner for GBM. This, and other work, supports the rationale for RestorGenex’s plans to advance RES-529 into clinical trials in GBM,” said David Sherris, Ph.D., chief scientific officer of RestorGenex.

This entry was posted in Recent Development News: Q1 - 2015. Bookmark the permalink.